Ubs Oconnor LLC Rapt Therapeutics, Inc. Call Options Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding RAPT
# of Institutions
105Shares Held
27.1MCall Options Held
26.7KPut Options Held
2.4K-
Vanguard Group Inc Valley Forge, PA3.16MShares$3.79 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$3.22 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.93 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2.07 Million0.42% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$1.92 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $35.6M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...